Scarica l'app Stockscreener
140.06
0.63%
0.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Form 144 PROTAGONIST THERAPEUTICS For: 1 October By Investing.com - Investing.com Canada
Form 144 | Protagonist Therapeutics(PTGX.US) Officer Proposes to Sell 8.26 Million in Common Stocks - Moomoo
Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares. - Stock Titan
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Protagonist Therapeutics stock gets USD 300.0 million buyback approval - AD HOC NEWS
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
Takeda wins FDA approval for MIMRYLO, triggers $275m payout to Protagonist - scanx.trade
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency - Montgomery Advertiser
The Peptide Boom That Isn’t About Your Muscles - WSJ
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma - Barchart.com
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - uk.finance.yahoo.com
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo! Finance Canada
Protagonist Therapeutics (PTGX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) stock price, news, quote and history - uk.finance.yahoo.com
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup - ChartMill
How Protagonist Therapeutics Inc. (PTGX) Affects Rotational Strategy Timing - Stock Traders Daily
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 20% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Protagonist Therapeutics stock holds near 52-week high as investors digest recent earnings - AD HOC NEWS
Protagonist Therapeutics stock gains as Bank of America builds a sizable stake - AD HOC NEWS
1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup - ChartMill
California State Teachers Retirement System Acquires 284 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com Australia
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing - Yahoo Finance
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Protagonist Therapeutics CEO sells $18.2m in shares - Investing.com India
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock - Moomoo
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com Nigeria
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock - MarketBeat
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Protagonist Therapeutics CEO highlights strong drug approvals and steady biotech progress in 2026. - Pluang
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com Nigeria
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
Up to $300 million could go toward buying back shares at Protagonist Therapeutics. - Stock Titan
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status - Yahoo Finance
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Yahoo Finance
Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - simplywall.st
Research Analysts Offer Predictions for PTGX Q1 Earnings - marketbeat.com
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 - ACCESS Newswire
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News - Yahoo Finance
Protagonist Therapeutics (NASDAQ:PTGX) Gets A Higher Price Target - Kalkine Media
BMO raises Protagonist Therapeutics price target on Mimrylo approval By Investing.com - Investing.com Canada
PTGX Maintained by BMO Capital -- Price Target Raised to $190 - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $190.00 Price Target at BMO Capital Markets - MarketBeat
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call - Yahoo Finance
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):